Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary,...
Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge
SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...
MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance
HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company,...
Sino Medical Sciences Secures Hong Kong Approval for Coronary Balloon Dilation Catheter
HONG KONG—Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in...
Hutchmed Withdraws Fruquintinib’s New Indication Application in China, Seeks Alternative Regulatory Path
HONG KONG—Hutchmed (HKG: 0013) has announced its decision to proactively withdraw the new indication application...
J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market
US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA)...
Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results
US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...
BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization
US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...
Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs
China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...
Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005
Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....
Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials
BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...
AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million
QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...
NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns
BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...
CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer
BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...
China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services
BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...
Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1
SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...
American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data
WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered...